NCT00109746|CompletedPhase 1/2DMC
Use of a Nutritional Supplement to Treat Diabetic Symptoms in HIV-Infected Adults
NT
A Novel Therapy for Glucose Intolerance in HIV Disease
Loading search results
Sponsor study identifier
interventional
39
1 country
1
Study Start
November 2005
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
May 2009
Actual (reported)Study Completion
June 2010
Actual (reported)The purpose of this study is to determine the effectiveness of the nutritional supplement chromium picolinate in improving insulin resistance, a symptom of diabetes, in HIV-infected patients. The ultimate goal is to find a simple therapy that can prevent the development of diabetes in individuals with HIV.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 2010
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2, 2005
Actual (reported)May 3, 2005
Actual (reported)November 2005
Date type not reportedThis date has not been verified as actual or estimated.
May 2009
Actual (reported)June 2010
Actual (reported)Improvement in insulin sensitivity
8 weeks
HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
State University of New York/General Clinical Research Center
Stony Brook, New York, 11794, United States
El-Sadr WM, Mullin CM, Carr A, Gibert C, Rappoport C, Visnegarwala F, Grunfeld C, Raghavan SS. Effects of HIV disease on lipid, glucose and insulin levels: results from a large antiretroviral-naive cohort. HIV Med. 2005 Mar;6(2):114-21. doi: 10.1111/j.1468-1293.2005.00273.x.
Howard AA, Floris-Moore M, Arnsten JH, Santoro N, Fleischer N, Lo Y, Schoenbaum EE. Disorders of glucose metabolism among HIV-infected women. Clin Infect Dis. 2005 May 15;40(10):1492-9. doi: 10.1086/429824. Epub 2005 Apr 11.
Marie C. Gelato, MD, PhD
State University of New York/General Clinical Research Center
39 participants (actual enrollment reported by the registry).
First Submitted
May 2, 2005
First Posted
May 3, 2005
Study Start
November 2005
Date type not reportedThis date has not been verified as actual or estimated.
Safety, Tolerability and Immune Response to LC002, an Experimental Therapeutic Vaccine, in Adults Receiving HAART
Contact the study team to confirm eligibility.
Taiwo BO. Insulin resistance, HIV infection, and anti-HIV therapies. AIDS Read. 2005 Apr;15(4):171-6, 179-80.
Primary Completion
May 2009
Actual (reported)Study Completion
June 2010
Actual (reported)Last Updated
March 23, 2016
Record last verified: 2013-05
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: